- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01650792
Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) (CLINICS)
CHADSS: Chagas Disease Scan Study
The main purpose of the study is to determine noninvasive markers of brain involvement in Chagas disease. In a subgroup of patients with high intensity transient signals (HITS) on transcranial Doppler monitorization, the investigators aim to determine the efficacy and safety of aspirin in preventing microembolization in patients with no previous history of stroke. Specific aims are listed bellow:
(1) to establish brain magnetic resonance imaging markers of stroke risk in patients with Chagasic heart failure (HF); (2) to determine whether biomarkers can predict stroke risk in patients with Chagasic HF; and (3) to evaluate the efficacy of antiplatelet treatment in decreasing microembolization rate in patients with Chagasic HF.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Bahia
-
Salvador, Bahia, Brazil, 40110060
- Recruiting
- Hospital Universitario Professor Edgard Santos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of heart failure according to Framingham criteria
- Informed consent
- Age 18 years or above
Exclusion Criteria:
- Patients with a history of an untreated malignancy (except local skin cancers)
- Ischemic stroke (determined using the Questionnaire for Verifying Stroke-Free Status (QVSFS)
- Patients on renal dialysis or with end-stage hepatic dysfunction
- Acute infection/inflammation (Temperature > 101.5 F, and/or WBC> 15, 000)
- Inability to obtain informed consent from patient or next of kin
- Anticoagulant use (warfarin or heparin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aspirin
Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
|
|
No Intervention: Best medical treatment
Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain magnetic resonance imaging lesions
Time Frame: Baseline cross-sectional data
|
Primary hypothesis is that silent brain infarcts, brain atrophy and white matter disease will be more common in patients with Chagas disease heart failure when compared to other etiologies of heart failure.
|
Baseline cross-sectional data
|
Biomarkers
Time Frame: Baseline cross-sectional data
|
Primary hypothesis is that serum biomarkers orosomucoid, neprilysin, interleukin-6 and matrix metalloproteinase-9 will be increased in Chagas disease heart failure when compared to other etiologies of heart failure
|
Baseline cross-sectional data
|
Proportion of high intensity transient signals on transcranial Doppler monitorization
Time Frame: One week
|
Primary hypothesis is that the proportion of patients with high intensity transient signals (HITS) on one-hour transcranial Doppler monitorization after one-week treatment with 300mg aspirin and best medical treatment will be less when compared with best medical treatment without aspirin
|
One week
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Trypanosomiasis
- Euglenozoa Infections
- Heart Failure
- Chagas Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- R01NS064905 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chagas Disease With Heart Failure
-
Fundación Cardiovascular de ColombiaCompletedChronic Heart Failure | Chagas CardiomyopathyColombia
-
InCor Heart InstituteJohnson & JohnsonUnknownHeart Failure | Chagas Cardiomyopathy | Chagas Disease | Heart Failure, SystolicBrazil
-
Evandro Chagas National Institute of Infectious...Completed
-
Institut de Recherche pour le DeveloppementInstituto de Investigación Hospital Universitario La PazCompletedChagas' Disease (Chronic) With Other Organ InvolvementBolivia
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Arrhythmia | Chagas Disease | Heart Failure, Congestive
-
University of BrasiliaCompletedHeart Failure | Chagas DiseaseBrazil
-
Cardurion Pharmaceuticals, Inc.TerminatedHeart Diseases | Cardiovascular Diseases | Heart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States, Israel, United Kingdom, Canada
-
Federal University of Minas GeraisCompletedHeart Failure | Chagas Cardiomyopathy | Dilated CardiomyopathyBrazil
-
Novartis PharmaceuticalsActive, not recruitingHeart Failure | Chagas DiseaseBrazil, Argentina, Mexico, Colombia
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA)CompletedHeart Failure | Heart Disease | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Cardiac FailureUnited States
Clinical Trials on Aspirin
-
The First Affiliated Hospital with Nanjing Medical...UnknownCoronary AtherosclerosisChina
-
Seoul National University HospitalCKD Pharmaceutical LimitedCompleted
-
Queen Mary University of LondonCancer Research UK; Barts and the London School of Medicine and DentistryCompletedProstate CancerUnited Kingdom
-
FANG HERecruitingPreeclampsia | Perinatal HaemorrhageChina
-
University of VigoRecruiting
-
Seoul National University HospitalCompletedCoronary Artery DiseaseKorea, Republic of
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPulmonary Disease, Chronic ObstructiveUnited States
-
Seoul National University HospitalCompletedHealthyKorea, Republic of
-
PLx PharmaCompletedDiabetes Mellitus, Type 2United States
-
BayerCompleted